Implementation status of pharmacological studies in the development of orphan drugs

Table 3 Target cancers in entrectinib development

Cancer with NTRK fusion gene expression	In vitro	In vivo	clinical trial (Phase II)		Approved indication
Cancer with NTRK fusion gene expression	Growth inhibition		Inclusion criteria	Enrolled n = 51	Approved indication
Non-small cell lung cancer	〇	〇	〇	9 (17.6%)	〇
Colorectal cancer	〇	〇		3 (5.9%)
Head and neck cancer		〇		0
Sarcoma		〇		13 (25.5%)
Other solid cancers				26 (51.1%)

Cancer cell lines were used for tumour growth inhibition studies and cancer types in patients enrolled in clinical trials
The tumour growth-inhibitory effect has been studied using several cancer cell lines, and the inclusion criteria for clinical trials were not limited to specific tumours

ISSN: 1750-1172